Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

PetVivo Holdings, Inc. PETV

Healthcare  —  Medical Devices
0.84 0.00 0.00% as of 25 Sep
Market cap
$12.9M
P/E
0.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

PetVivo Holdings, Inc. (PETV) Business Profile

Updated before January 2025

Company Overview

PetVivo Holdings, Inc. (NASDAQ: PETV) is a forward-thinking biomedical device company specializing in the development and commercialization of innovative medical products for the companion animal market. Founded in 2013 and headquartered in Minneapolis, Minnesota, PetVivo is committed to improving the quality of life for pets by addressing unmet medical needs in veterinary medicine. The company is led by a team of seasoned professionals, including John Lai, the CEO, who brings extensive experience in business development and strategic planning. Other key members of the leadership team include Randall Meyer, COO, and David Deming, CFO, who collectively drive the company’s vision and operational excellence.

Core Business Segments

PetVivo focuses on the development and commercialization of proprietary medical devices and therapeutics for pets. The company’s flagship product is Spryng™ with OsteoCushion™ Technology, a groundbreaking injectable veterinary device designed to manage osteoarthritis and joint-related issues in dogs, horses, and other animals.

Key Products and Services:

  1. Spryng™ with OsteoCushion™ Technology:

    • A patented, protein-based biomaterial that mimics cartilage and provides cushioning and support to joints.
    • Designed to alleviate pain and improve mobility in animals suffering from osteoarthritis or other joint conditions.
    • Offers a minimally invasive alternative to surgery and long-term pharmaceutical treatments.

  2. Veterinary Training and Support Services:

    • PetVivo provides comprehensive training programs for veterinarians to ensure the effective use of Spryng™.
    • Ongoing customer support and educational resources are offered to veterinary clinics.

  3. Pipeline Products:

    • PetVivo is actively developing additional therapeutic solutions for other chronic conditions in pets, including soft tissue injuries and degenerative diseases.

Business Model

PetVivo operates on a business-to-business (B2B) model, targeting veterinary clinics, hospitals, and distributors as its primary customers. The company generates revenue through the sale of its proprietary products, particularly Spryng™, and by offering training and support services to veterinary professionals. PetVivo’s business model emphasizes:

  • Innovation: Continuous investment in research and development to expand its product portfolio.
  • Education: Providing veterinarians with the knowledge and tools needed to adopt and implement its products effectively.
  • Scalability: Leveraging partnerships with distributors to expand its market reach and drive sales growth.

Strategic Direction

PetVivo is focused on becoming a leader in the veterinary medical device market by pursuing the following strategic initiatives:

  1. Product Expansion:

    • Development of new therapeutic solutions targeting a broader range of chronic conditions in pets.
    • Exploration of applications for Spryng™ in additional animal species.

  2. Market Penetration:

    • Strengthening relationships with veterinary clinics and distributors to increase adoption of Spryng™.
    • Expanding its presence in international markets.

  3. Sustainability Goals:

    • Commitment to environmentally friendly manufacturing processes.
    • Development of biodegradable and sustainable materials for future products.

  4. Research and Development:

    • Collaborating with academic institutions and research organizations to advance veterinary medicine.
    • Conducting clinical studies to validate the efficacy and safety of its products.

Competitive Landscape

PetVivo operates in a competitive market, facing challenges from established players in the veterinary medical device and pharmaceutical sectors. Key competitors include:

  • Zoetis Inc.: A global leader in animal health, offering a wide range of pharmaceuticals, vaccines, and diagnostic products.
  • Elanco Animal Health: Specializes in innovative solutions for animal health, including treatments for chronic conditions.
  • Arthrex Vet Systems: Focuses on orthopedic solutions for animals, including surgical implants and devices.

Despite the competition, PetVivo differentiates itself through its unique product offerings, such as Spryng™, which addresses unmet needs in the market.

Risk Factors

PetVivo faces several risks that could impact its business operations and financial performance:

  1. Market Dependence:

    • Reliance on the success of Spryng™ as its primary revenue driver.
    • Limited diversification in its product portfolio.

  2. Regulatory Challenges:

    • Compliance with stringent regulatory requirements for medical devices and therapeutics.
    • Potential delays in obtaining approvals for new products.

  3. Supply Chain Disruptions:

    • Dependence on third-party manufacturers and suppliers for raw materials and production.
    • Vulnerability to global supply chain issues, such as shortages and transportation delays.

  4. Competitive Pressure:

    • Intense competition from larger, well-established companies with greater resources.
    • Risk of new entrants offering similar or superior products.

Recent Developments

PetVivo has made significant strides in recent years, including:

  • Launch of Spryng™: Expanded availability of its flagship product to veterinary clinics across the United States.
  • Partnerships: Collaborated with distributors to enhance market penetration and streamline product delivery.
  • Clinical Studies: Conducted research to demonstrate the efficacy and safety of Spryng™, further validating its value proposition.
  • Global Developments: Adapted to challenges posed by the COVID-19 pandemic, including supply chain disruptions and shifts in veterinary care practices.

Investment Considerations

Strengths:

  • Innovative product portfolio addressing unmet needs in veterinary medicine.
  • Strong leadership team with extensive industry experience.
  • Growing market demand for pet healthcare solutions.
  • Focus on sustainability and environmentally friendly practices.

Risks:

  • Dependence on a single flagship product for revenue generation.
  • Exposure to regulatory and competitive pressures.
  • Potential supply chain disruptions impacting production and delivery.

Conclusion

PetVivo Holdings, Inc. is well-positioned to capitalize on the growing demand for innovative veterinary medical devices. With its unique product offerings, strong leadership, and commitment to research and development, the company has the potential to achieve significant growth in the coming years. However, investors should carefully consider the associated risks, including market dependence and competitive pressures, before making investment decisions. Overall, PetVivo represents a promising opportunity in the rapidly expanding companion animal healthcare market.